Tenaya's TN-201 shows robust cardiac transduction, increasing mRNA and protein in 3 HCM patients

Tenaya Therapeutics, Inc.

TN-201 well tolerated at 3E13 vg/kg; no cardiac toxicities or TMA; liver enzyme elevations managed with corticosteroids.
Robust cardiac transduction at Week 8 above preclinical efficacy levels; TN-201 mRNA increased 50% at Week 52 in Patient 1.
MyBP-C protein level increased 3% from Week 8 to 52 in Patient 1; baseline biopsies added for future quantification.
Clinical measures mostly stable/improved: NT-proBNP stable, troponin I normalized in Patient 2; NYHA class improved.
Further data from Cohort 1 and higher-dose Cohort 2 expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.